has function has role immunizes against disease immunizes recipient leukemia Homo sapiens therapeutic vaccine function vaccine in clinical trial role leukemia cancer vaccine therapeutic cancer vaccine multipeptide XS15 vaccine Gene name: TLR2 NCT: https://clinicaltrials.gov/study/NCT04688385 Gene name: TLR1 Jie Zheng 7097 7096 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179595 A cancer vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological malignancies without any approved treatment options. Hayleigh Kahn cancer vaccine 6319 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6319 NCT: https://clinicaltrials.gov/study/NCT05014607